Cigna Corp
NYSE:CI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
257.49
366.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cigna Corp
Cigna Corp
Cash & Cash Equivalents
Cigna Corp
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cigna Corp
NYSE:CI
|
Cash & Cash Equivalents
$5.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
DaVita Inc
NYSE:DVA
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Chemed Corp
NYSE:CHE
|
Cash & Cash Equivalents
$238.5m
|
CAGR 3-Years
102%
|
CAGR 5-Years
92%
|
CAGR 10-Years
29%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cash & Cash Equivalents
$764m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cash & Cash Equivalents
$6.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
20%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cash & Cash Equivalents
$1.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
33%
|
CAGR 10-Years
10%
|
|
Cigna Corp
Glance View
Cigna Corporation, a global health services company, is on a mission to improve the health and well-being of its customers while ensuring they have access to affordable healthcare. With a history that dates back to the early 1980s, Cigna has evolved into a diversified organization offering a wide range of products and services. The company operates primarily in the health insurance sector, providing coverage for individuals, families, and large employer groups. One notable aspect of Cigna’s portfolio is its integrated approach, combining insurance with healthcare services, which includes behavioral health, disability, and wellness programs. This unique structure positions Cigna strategically to enhance member engagement and health outcomes, while also streamlining costs, a crucial factor in today’s fiercely competitive healthcare landscape. At the core of Cigna's value proposition is its commitment to innovation and customer-centric solutions. The company leverages advanced data analytics and technology to tailor services to meet the needs of a diverse customer base. For investors, Cigna represents a compelling opportunity, driven by robust revenue growth and a focus on strategic mergers and acquisitions that expand its reach. Notably, the company’s acquisition of Express Scripts in 2018 marked a significant pivot towards integrated healthcare management, allowing it to capture more value across the healthcare ecosystem. With a strong balance sheet, consistent dividend payments, and a solid track record of operational efficiency, Cigna is ideally positioned to capitalize on the growing demand for comprehensive healthcare solutions, making it a noteworthy consideration for those seeking to invest in the evolving health services sector.
See Also
What is Cigna Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
5.9B
USD
Based on the financial report for Sep 30, 2024, Cigna Corp's Cash & Cash Equivalents amounts to 5.9B USD.
What is Cigna Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
14%
Over the last year, the Cash & Cash Equivalents growth was -31%. The average annual Cash & Cash Equivalents growth rates for Cigna Corp have been 19% over the past three years , 5% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
